TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06737744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Games for Change (AG4C)
Description: This intervention was carried out in Turkiye within the Erasmus+ Key Action 3 project titled Active Games for Change (AG4C). The programme included a series of innovative, face-to-face active games with a non-formal approach that prioritised physical activity, specifically designed to support the development of social and emotional competencies identified for the first time in the field in a probation directorate serving young adult offenders.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Games for Change Group Working
Description: The Active Games for Change intervention program was implemented in Izmir, Türkiye within the Erasmus+ Key Action 3 project titled Active Games for Change (AG4C). The AG4C intervention program included a series of innovative, face-to-face active games with a non-formal approach that prioritised support for developing social and emotional competencies of young adults with substance use problems, for the first time in the field.
Study: NCT06738901

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SKP-0141
Description: Human plasma-derived coagulation factor VIII concentrate
Study: NCT06738745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-2189
Description: HRS-2189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5041
Description: HRS-5041
Study: NCT05722496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic pedaling exercise
Description: aerobic exercise in the form of leg pedaling exercise in semi-supine position using leg ergometer by different intensities

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic pedaling exercise
Description: aerobic exercise in the form of leg pedaling exercise in semi-supine position using leg ergometer by different intensities
Study: NCT05031858

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory physiotherapy
Description: Respiratory physiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory physiotherapy
Description: Respiratory physiotherapy
Study: NCT05269238

Intervention type: OTHER
Group type: OTHER
Intervention: performing lumbar punctures by students with standard training
Description: performance of the puncture by the student have been previously trained with standard training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training students augmented reality simulator
Description: performance of the puncture by the student have been previously trained using the augmented reality simulator
Study: NCT05591729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercises
Description: Each Pilates session will last for one hour. The subjects will be taught the 5 key elements of Pilates (lateral costal breathing, centering which is a neutral position of the lumbar spine with activation of the core muscles, ribcage placement, shoulder blade placement and neutral position of the cervical spine with slight upper cervical flexion at the craniocervical junction). A pilates exercise program will consist of 11 levels of treatment program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: postural correction exercise
Description: the patients will receive postural correction exercises, stretches, and exercises to the pectoralis major, elevator scapulae, upper trapezius, serratus anterior, rhomboids, and deep neck flexors. The stretches included sitting chair stretches, Brugger's, wall angels, and doorway stretches. The exercises included push-up-plus, head-neck-retraction, and Kibler squeeze

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: postural correction exercise
Description: the patients will receive postural correction exercises, stretches, and exercises to the pectoralis major, elevator scapulae, upper trapezius, serratus anterior, rhomboids, and deep neck flexors. The stretches included sitting chair stretches, Brugger's, wall angels, and doorway stretches. The exercises included push-up-plus, head-neck-retraction, and Kibler squeeze
Study: NCT04651296

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: health education
Description: manualized health education group
Study: NCT06738290

Intervention type: BEHAVIORAL
Intervention: Targeted home-based touchscreen training
Description: Participants will practice the Swipe-Slide Pattern (SSP) task independently at home in both ST and DT condition, offered in a random order. During this task, participants perform different pre-defined patterns by moving their finger over a touchscreen, resembling a touchscreen unlock trace. The DT condition includes the SSP-task while counting either red or green lights illuminated on the screen. They will receive 10 training sessions of the SSP-task over a period of two weeks. Each week will consist of 5 consecutive days of training for approximately 10 min. per session. Participants will perform 9 trials of 12 patterns each, alternated with rest periods of 14s. Instruction and answers are also included. Feedback will be provided during the rest periods.
Study: NCT06734819

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Storytelling Video
Description: The Living Donation Storytelling Project (LDSP) is an online video library of living donation first-person narratives aiming to inspire more people to consider LDKT (https://livingdonationstories.org/).17 As of 2020, the library has 118 stories from living donors and kidney recipients sharing their experiences with the pursuit, challenges and outcomes of transplant.18,19 Four videos were selected from the LDSP and edited to standardized duration and thematic content. Videos were cut to three minutes in length and covered the topics of 1) challenges faced when seeking LDKT, 2) life after LDKT and 3) advice for other patients considering LDKT.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Patient Education
Description: Standard of care patient education materials include verbal didactic offered during the surgical consult and pamphlets produced by Vancouver Coastal Health.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Patient Education
Description: Standard of care patient education materials include verbal didactic offered during the surgical consult and pamphlets produced by Vancouver Coastal Health.
Study: NCT06739473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movies
Description: Participants will watch eight short movie clips, and the changes different emotions evoked by the clips will be studied using H2\[15O\]O PET/CT.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cold
Description: Participants will be studied with H2\[15O\]O PET/CT while one of their legs will be exposed to cold to study the effects of cold stimulus on whole-body blood flow.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic euglycemic clamp
Description: Participants will be administered intravenous fast acting insulin (NovoRapid, Novo Nordisk, 1 mU/m2 body surface area/min) together with 20 % glucose to maintain normal glucose values (5.0 mmol/L) to study the effects of insulin on whole body blood flow with H2\[15O\]O PET/CT, and to assess tissue insulin-stimulated glucose uptake with \[18F\]FDG PET/CT.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: H2[15O]O PET/CT
Description: H2\[15O\]O PET/CT, with a dose of 25-700 MB/bolus repeated 2-8 times per scan.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: H2[15O]O PET/CT
Description: H2\[15O\]O PET/CT, with a dose of 25-700 MB/bolus repeated 2-8 times per scan.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]FDG PET/CT
Description: Whole-body \[18F\]FDG PET/CT scan to study tissue glucose uptake, dose 100 MBq

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEUS or Contrast enhanced Ultrasound
Description: Contrast-enhanced ultrasound of left forearm muscles is performed during fasting and after 30-40 minutes of hyperinsulinemia
Study: NCT06739759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antagonist protocol for IVF
Description: antagonist protocol with triggering by Decapeptyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modified Agonist protocol for IVF with additive treatments as HCQ
Description: giving additive drugs to agonist protocolas HCQ
Study: NCT04814186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis
Description: 61 mg, once daily, oral administration, for 12 months.
Study: NCT05466474

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tislelizumab Injection
Description: Efficacy of tislelizumab or tislelizumab combined with dacarbazine in the treatment of advanced malignant melanoma.
Study: NCT05171530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus taxane drugs
Description: * Drug: Paclitaxel Dose: 135mg/m2 Other Name: PTX~* Drug: Docetaxel Dose: 75mg/m2 Other Name: FA~* Drug: Lenvatinib Dose: 4mg, 8mg, 12mg,16mg Other Name: FA
Study: NCT04084743

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality intervention
Description: Virtual reality intervention includes: Maze game software

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality intervention
Description: Virtual reality intervention includes: Maze game software

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dual task intervention
Description: The intervention combined both motor and cognitive training which includes, walking 10 meter (1) Free walking (2) Walking carrying an emptying tray (3) Walking carrying a tray with 4 empty glasses (4) Digit calculations (Counting forward and backward, addition, subtraction, multiplication and division) during walking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual task intervention
Description: The intervention combined both motor and cognitive training which includes, walking 10 meter (1) Free walking (2) Walking carrying an emptying tray (3) Walking carrying a tray with 4 empty glasses (4) Digit calculations (Counting forward and backward, addition, subtraction, multiplication and division) during walking.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: 1. Gait training in parallel bar~2. Balance activities which includes, a. Forward direction activity b. Backward direction activity c. Sideways direction activity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Description: 1. Gait training in parallel bar~2. Balance activities which includes, a. Forward direction activity b. Backward direction activity c. Sideways direction activity
Study: NCT06451744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples collection
Description: 50 mL blood sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples collection
Description: 50 mL blood sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples collection
Description: 50 mL blood sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples collection
Description: 50 mL blood sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples collection
Description: 50 mL blood sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples collection
Description: 50 mL blood sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples collection
Description: 50 mL blood sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin or mucous membrane brushing
Description: brushing on skin or mucous membrane lesions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin or mucous membrane brushing
Description: brushing on skin or mucous membrane lesions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin or mucous membrane brushing
Description: brushing on skin or mucous membrane lesions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin or mucous membrane brushing
Description: brushing on skin or mucous membrane lesions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin or mucous membrane brushing
Description: brushing on skin or mucous membrane lesions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin or mucous membrane brushing
Description: brushing on skin or mucous membrane lesions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin or mucous membrane brushing
Description: brushing on skin or mucous membrane lesions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin or mucous membrane biopsy
Description: 6 mm biopsy
Study: NCT05069974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg
Description: After randomized to the experimental arm, the patient will take 1 tablet of Linezolid every 12hours during 10 days or 1 tablet of of Linezolid every 24hours during 5 days.
Study: NCT06451744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin or mucous membrane biopsy
Description: 6 mm biopsy
Study: NCT04157790

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CARE score
Description: CARE score calculation
Study: NCT05069974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg
Description: After randomized to the experimental arm, the patient will take 1 tablet of Linezolid every 12hours during 10 days or 1 tablet of of Linezolid every 24hours during 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzathine Penicilllin G
Description: After randomized to the control arm, the patient will receive a single dose of intramuscular BPG.
Study: NCT06263842

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified Elamrousy approach for socket shield technique
Description: the jumping gap will be filled with AWTG

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional socket shield
Description: the jumping gap will be left ungrafted

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: combined socket shild with xenograft
Description: the jumping gap will be filled with xenograft
Study: NCT05014438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986166
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986166
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986166
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branebrutinib
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT06200480

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone by nurse
Description: Patient-initiated follow-up at week 2 and 6
Study: NCT06462573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: locally infilterating anaethesia like lidocaine
Description: which patients will undergo ESWL under locally infiltrated anaesthetic. Using ultrasound guidance, the quadratus lumborum muscle will be identified. Then a mixture of 0.5 % bupivacaine (10 ml) and 2 % lidocaine (10 ml) will be injected into the muscle as a single shot 20 minutes before the procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: general anaethesia
Description: which patients will undergo ESWL under systemic analgesia. The latter will be achieved using one gram of paracetamol IV infusion at the beginning of the procedure.~In case of unsatisfactory pain control in either group, systemic analgesia using IV Ketorolac injection will be used on demand or the required dose will be recorded at the end of the session.
Study: NCT06491927

Intervention type: GENETIC
Intervention: No Intervention
Description: Observational study
Study: NCT05356611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engage
Description: Engage is a 9-week, behavioral-based, psychotherapy treatment protocol for late-life depression.
Study: NCT05852717

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AutoSCT OR CAR T-cell Therapy
Description: Autologous stem cell transplant (AutoSCT) or CAR T-cell therapy will be performed after Cycle 3 of receiving epcoritamab and GDP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDP
Description: Gemcitabine Cisplatin Dexamethasone
Study: NCT06452758

Intervention type: OTHER
Intervention: 2000 meter ergometer test
Description: Rowers will perform 2000m ergometer test. A 2,000-meter trial is a standard test used to assess performance in rowers.
Study: NCT06550869

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior Quadratus Lumborum Block at the lateral supra-arcuate ligament under laparoscopic direct vision
Description: The urologists find the inner arcuate ligament. The scalp needle is inserted from the midpoint of the lower edge of the inner or outer arcuate ligament towards the head to the dorsal side of the diaphragm. After withdrawing without blood, air, or cerebrospinal fluid, 2 ml of normal saline is first administered to observe the fluid spreading towards the head Then, 20 ml of 0.375% ropivacaine hydrochloride injection is administered.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration anesthesia
Description: The urologists give local infiltration anesthesia with 20 ml of 0.375% ropivacaine hydrochloride injection.
Study: NCT05509023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-914
Description: Subcutaneous administration of ADX-914

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous administration of Placebo
Study: NCT05795959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Receive education on precision medicine
Description: Patients who consent to participating in the study and are randomized to the intervention group, will meet 1 on 1 with a trained lay VA volunteer. The trained lay VA volunteer will conduct phone calls with patients until the end of the 1 month enrollment period to deliver education regarding precision medicine.
Study: NCT06372119

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole-stimulated cycle strategy
Description: Letrozole (Femara® 2.5 milligrams, Novartis, Switzerland or Lezra® 2.5 milligrams, Actavis, Rumani) 5 milligrams/day for 5 days, starting on the second to fourth day of the menstrual cycle.~Post-letrozole, ultrasound checks follicle growth. If ≥18mm, Ovitrelle® 250 mcg (Merck, Kenilworth, New Jersey, USA) induces ovulation.~Luteal phase support with vaginal micronized progesterone (Cyclogest® 400 milligrams, Actavis, UK or Utrogestan® 200 milligrams, Besins, Belgium) 800 milligrams/day starting two days post-hCG.~Embryo transfer, 5 days post-progesterone. Ultrasounds use Samsung HS-30, vaginal probe, and ≥7.5MHz frequency. Hormonal support until the 12th gestational week with vaginal micronized progesterone 800 milligrams/day.~Cycle cancellation criteria: no follicle development on day 21 from the day of starting letrozole, spontaneous ovulation, letrozole intolerance, fluid retention. Cycle cancellation will be noted as a study's outcome.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Artificial cycle strategy
Description: Oral estradiol valerate (Progynova® 2 milligrams, Bayer Pharma AG, Germany or Valiera® 2 milligrams, Laboratories Recalcine, Chile) 6 milligrams/day for 10 days, starting on the second to fourth day of the menstrual cycle.~Post-estradiol, ultrasound checks endometrial thickness. If ≥7mm, start vaginal micronized progesterone (Cyclogest® 400 milligrams, Actavis, UK or Utrogestan® 200 milligrams, Besins, Belgium) 800 milligrams/day. If \<7mm, increase the dose of oral estradiol valerate to 8 milligrams/day (5-6 days) and 12 milligrams/day (5-6 days).~Embryo transfer, 5 days post-progesterone. Ultrasounds use Samsung HS-30, vaginal probe, and ≥7.5MHz frequency. Hormonal support until the 12th gestational week with vaginal micronized progesterone 800 milligrams/day.~Cycle cancellation criteria: endometrial thickness \<7mm on day 21 of using estradiol, spontaneous ovulation, oral estradiol valerate intolerance, fluid retention. Cycle cancellation will be noted as a study's outcome.
Study: NCT05803135

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iguratimod combined with Tofacitinib;
Description: Iguratimod (taken orally, 25mg, bid, daily) combined with Tofacitinib (taken orally, 5mg, bid, daily); Placebo of Iguratimod (taken orally, 25mg, bid, daily) combined with Tofacitinib (taken orally, 5mg, bid, daily)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iguratimod combined with Tofacitinib;
Description: Iguratimod (taken orally, 25mg, bid, daily) combined with Tofacitinib (taken orally, 5mg, bid, daily); Placebo of Iguratimod (taken orally, 25mg, bid, daily) combined with Tofacitinib (taken orally, 5mg, bid, daily)
Study: NCT05010135

Intervention type: DEVICE
Intervention: Zebris Gait System assessment for gait weight distribution + EMG evaluation of Quadriceps, Hamstrings, Tib Anterior and Calves + Positional Sense assessment
Description: To measure the above parameters and to compare between the healthy subjects and the vertebral fracture subjects

Intervention type: DEVICE
Intervention: Zebris Gait System assessment for gait weight distribution + EMG evaluation of Quadriceps, Hamstrings, Tib Anterior and Calves + Positional Sense assessment
Description: To measure the above parameters and to compare between the healthy subjects and the vertebral fracture subjects
Study: NCT05448209

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walking exercise
Description: Intervention Group Afterwards, patients taking paclitaxel-paclitaxel-herceptin will be given a nurse-led Motivational Interview about CIPN, physical activity and regular physical activity-walking. Patients will be instructed that the goal is to beat the previous number of steps each time. If he/she has problems/shortness of breath, chest pain, palpitation complaints during walking, he/she will be told to take a break from walking and rest. The study will be conducted under the supervision of a Medical Oncology specialist throughout the study, as well as the controls of patients with ongoing symptoms. Participants will be given a pedometer for regular follow-up, its use will be explained, and it will be told to mark it on the walking tracking chart. It will be emphasized that rhythmic walking is important for the pedometer to count correctly. Motivational Interview sessions will be conducted face-to-face at the beginning, week 4 and week 8.
Study: NCT04246229

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubinometry
Description: use of transcutaneous bilirubinometry a non-invasieve measurement of skin bilirubin levels

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum bilirubin
Description: use of blood draws to measure serum bilirubin level
Study: NCT05852717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDP
Description: Gemcitabine Cisplatin Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Epcoritamab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Epcoritamab